Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Prevalence of Fast Progression in the Central versus Global Visual Field Across Varying Glaucoma Severity Groups
Author Affiliations & Notes
  • Gopikasree Gunasegaran
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Sasan Moghimi
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Takashi Nishida
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Jeffrey M Liebmann
    Ophthalmology, Columbia University, New York, New York, United States
  • Massimo Antonio Fazio
    Ophthalmology, The University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Christopher A Girkin
    Ophthalmology, The University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Jo-Hsuan Wu
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Golnoush Mahmoudinezhad
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Linda M Zangwill
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Robert Weinreb
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Gopikasree Gunasegaran None; Sasan Moghimi National Eye Institute, University of California Tobacco Related Disease Research Program., Code F (Financial Support); Takashi Nishida Topcon, Code C (Consultant/Contractor); Jeffrey Liebmann Allergan, Genentech, Thea, Bausch & Lomb, Code C (Consultant/Contractor), Novartis, Research to Prevent Blindness , Code F (Financial Support); Massimo Fazio National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, and funding support from Heidelberg Engineering, Topcon Healthcare, Code F (Financial Support); Christopher Girkin National Eye Institute, Heidelberg Engineering, Topcon, EyeSight Foundation of Alabama, Research to Prevent Blindness, GmbH , Code F (Financial Support); Jo-Hsuan Wu None; Golnoush Mahmoudinezhad None; Linda Zangwill Abbvie, Topcon F: National Eye Institute, Carl Zeiss Meditec, Optovue, Heidelberg Engineering, and Topcon, Code C (Consultant/Contractor), Carl Zeiss Meditec, Code P (Patent); Robert Weinreb Abbvie, Aerie Pharmaceuticals, Alcon, Allergan, Amydis, Equinox, Eyenovia, Iantrek, IOPtic,  Implandata, Nicox, Santen, and Topcon, Code C (Consultant/Contractor), National Eye Institute, Heidelberg Engineering, Carl  Zeiss Meditec, Konan Medical, Optovue, Zilia, Centervue, and Topcon, Code F (Financial Support), Toromedes, Carl Zeiss Meditec, Code P (Patent)
  • Footnotes
    Support  National Eye Institute (R01EY034148, R01EY029058, R01EY11008, R01EY019869, R01EY027510, R01EY026574, P30EY022589); an unrestricted grant from Research to Prevent Blindness; UC Tobacco Related Disease Research Program (T31IP1511); and grants for participants’ glaucoma medications from Novartis/Alcon Laboratories Inc, Allergan, Akorn, Pfizer, Merck, and Santen.
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2523. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gopikasree Gunasegaran, Sasan Moghimi, Takashi Nishida, Jeffrey M Liebmann, Massimo Antonio Fazio, Christopher A Girkin, Jo-Hsuan Wu, Golnoush Mahmoudinezhad, Linda M Zangwill, Robert Weinreb; Prevalence of Fast Progression in the Central versus Global Visual Field Across Varying Glaucoma Severity Groups. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2523.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the prevalence of fast central visual field (VF) progression with global VF progression in individuals with glaucoma receiving routine clinical care across different stages of glaucoma severity at baseline.

Methods : This study included 1117 eyes of 759 participants with primary open-angle glaucoma (POAG) with at least five 24-2 VF tests over a minimum of 2-year follow-up. Eyes were classified as early (> -6 dB), moderate (-6 dB to -12 dB), and advanced (-12 dB to -20 dB) based on baseline VF mean deviation (MD). The slopes of global MD and central mean total deviation (MTD10) (12 test points within the central 10° region of 24-2 VF test) were calculated. Proportions of fast progressors (≤ -1.0 dB/year MD and ≤ -0.5 dB/year for MTD10) in each glaucoma severity group were determined.

Results : Overall, 7.5% of eyes demonstrated fast rates of progression based on MD, while 12.8% of eyes showed fast rates of progression based on MTD10. When eyes were stratified by baseline glaucoma severity, 6.9% (early), 11.1% (moderate), and 5.8% (advanced) of eyes exhibited fast rates of progression based on MD. Although fast MTD10 progressors were most prevalent in the advanced glaucoma group (20.9%), a notable proportion of eyes with early (10.8%) and moderate glaucoma (15.2%) also exhibited fast rates of change centrally. A considerable proportion of eyes showed fast rates of progression based on MTD10 without concurrent fast MD progression consistent across all glaucoma severity groups [5.5% (early glaucoma), 6.6% (moderate glaucoma), and 15.1% (advanced glaucoma)]. In contrast, fast progression based on MD was detected in isolation in a much smaller proportions of patients (1.7% in early glaucoma, 2.5% in moderate glaucoma, and none in advanced glaucoma).

Conclusions : Selective analysis of the MTD10 detected a greater proportion of eyes that exhibited fast progression across all disease severity groups compared to measurements from the entire VF, underscoring the importance of close monitoring for progressive central VF changes in all stages of glaucoma.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Slow and fast progressors based on rates of change of MD and MTD10. Eyes are grouped in levels of visual field severity at baseline.

Slow and fast progressors based on rates of change of MD and MTD10. Eyes are grouped in levels of visual field severity at baseline.

 

Proportion of eyes classified as fast progressors based on MD and MTD10 across different stages of glaucoma severity at baseline.

Proportion of eyes classified as fast progressors based on MD and MTD10 across different stages of glaucoma severity at baseline.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×